Tuberous Sclerosis Complex
Released: January 7, 2021
Defense Health Program
Department of Defense Tuberous Sclerosis Complex Research Program
Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
Although the Fiscal Year 2021 (FY21) Defense Appropriations Bill has been signed into law, the FY21 appropriation for the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) is contingent upon the outcome of a pending rescissions request. The TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY21 Defense Appropriations Act is anticipated to provide $8M to the Department of Defense TSCRP to support innovative, high-impact tuberous sclerosis complex (TSC) research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
Subject to the FY21 Congressional appropriation for TSCRP funding, FY21 TSCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
Applications submitted to the FY21 TSCRP are encouraged to address one or more of the following Focus Areas:
- Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
- Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures
- Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological and behavioral interventions
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Exploration - Hypothesis Development Award||Investigators at or above postdoctoral fellow (or equivalent).||
|Idea Development Award||
Independent investigators at or above the level of Assistant Professor (or equivalent);
Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a Principal Investigator of one or more Federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K Awardees are eligible to apply.)
Must not have received a New Investigator Award previously from any program within the CDMRP.
|Clinical Translational Research Award||Independent investigators at or above the level of Assistant Professor (or equivalent).||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Thursday, May 26, 2022